PLRX

10.75

0.84% 0.09

Handel nachbörslich: 10.75

Pliant Therapeutics Inc (PLRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.66

Offen:

$10.68

24-Stunden-Volumen:

521.51K

Relative Volume:

1.07

Marktkapitalisierung:

$654.18M

Einnahmen:

$5.03M

Nettoeinkommen (Verlust:

$-185.41M

KGV:

-3.479

EPS:

-3.09

Netto-Cashflow:

$-139.79M

1W Leistung:

-1.56%

1M Leistung:

-18.38%

6M Leistung:

-24.88%

1J Leistung:

-40.01%

1-Tages-Spanne:

$10.54

$11.06

1-Wochen-Bereich:

$10.54

$11.40

52-Wochen-Spanne:

$10.22

$18.46

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Firmenname

Pliant Therapeutics Inc

Sektor

Healthcare (1173)

Branche

Biotechnology (678)

Telefon

650-481-6770

Adresse

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Mitarbeiter

166

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PLRX's Discussions on Twitter

Vergleichen Sie PLRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PLRX Pliant Therapeutics Inc	10.75	654.18M	5.03M	-185.41M	-139.79M	-3.09
VRTX Vertex Pharmaceuticals Inc	461.68	118.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	672.98	73.95B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	655.13	39.81B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	271.31	34.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	123.77	29.67B	3.30B	-501.07M	1.03B	-2.1146

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-09	Fortgesetzt	Leerink Partners	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-05-18	Eingeleitet	Canaccord Genuity	Buy
2023-04-13	Eingeleitet	Robert W. Baird	Outperform
2022-12-14	Eingeleitet	Stifel	Buy
2022-12-07	Eingeleitet	JP Morgan	Overweight
2022-09-01	Eingeleitet	Citigroup	Buy
2022-07-20	Eingeleitet	SVB Leerink	Outperform
2022-05-25	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-10	Eingeleitet	Oppenheimer	Outperform
2021-11-24	Eingeleitet	RBC Capital Mkts	Outperform
2021-11-03	Eingeleitet	H.C. Wainwright	Buy
2021-04-20	Eingeleitet	BTIG Research	Buy
2021-04-05	Eingeleitet	Citigroup	Buy
2020-06-29	Eingeleitet	Citigroup	Buy
2020-06-29	Eingeleitet	Cowen	Outperform
2020-06-29	Eingeleitet	Needham	Buy
2020-06-29	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten

Jan 27, 2025

(PLRX) Proactive Strategies - Stock Traders Daily

Jan 27, 2025

Jan 24, 2025

PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com

Jan 24, 2025

Pliant Therapeutics' chief human resource officer sells $41,892 in stock By Investing.com - Investing.com South Africa

Jan 24, 2025

Jan 23, 2025

Insider Selling: Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells 10,230 Shares of Stock - MarketBeat

Jan 23, 2025

Bernard Coulie Sells 52,419 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock - MarketBeat

Jan 23, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 13,270 Shares - MarketBeat

Jan 23, 2025

Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN

Jan 23, 2025

Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock - Investing.com India

Jan 23, 2025

Pliant Therapeutics chief business officer Hull sells $178,500 in stock By Investing.com - Investing.com Australia

Jan 23, 2025

Brokers Issue Forecasts for PLRX FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 - MSN

Jan 22, 2025

Pliant Therapeutics CFO sells $225,679 in stock By Investing.com - Investing.com Canada

Jan 22, 2025

Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 By Investing.com - Investing.com South Africa

Jan 22, 2025

Pliant Therapeutics CFO sells $225,679 in stock - MSN

Jan 22, 2025

Pliant Therapeutics chief business officer Hull sells $178,500 in stock - Investing.com India

Jan 22, 2025

Pliant Therapeutics' chief medical officer sells $206,973 in stock By Investing.com - Investing.com South Africa

Jan 22, 2025

Pliant Therapeutics' chief medical officer sells $206,973 in stock - Investing.com

Jan 22, 2025

Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock By Investing.com - Investing.com UK

Jan 22, 2025

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 22, 2025

Pliant Therapeutics Grants 275,000 Stock Options to New Chief Technical Officer - StockTitan

Jan 22, 2025

Pliant Therapeutics appoints new Chief Technical Officer By Investing.com - Investing.com Australia

Jan 22, 2025

Pliant Therapeutics appoints new Chief Technical Officer - Investing.com

Jan 22, 2025

Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer - GlobeNewswire

Jan 22, 2025

Pliant Therapeutics Strengthens Leadership Team with Veteran CTO Appointment for Commercial Push - StockTitan

Jan 22, 2025

Cantor Fitzgerald Forecasts PLRX FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 21, 2025

Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis - Defense World

Jan 21, 2025

Jan 19, 2025

PLRX (Pliant Therapeutics) 3-Year EPS without NRI Growth Ra - GuruFocus.com

Jan 19, 2025

Jan 18, 2025

PLRX (Pliant Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com

Jan 18, 2025

Jan 17, 2025

Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.2%Here's Why - MarketBeat

Jan 17, 2025

Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily

Jan 17, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Jan 17, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jan 17, 2025

Jan 15, 2025

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 11%Still a Buy? - MarketBeat

Jan 15, 2025

Jan 02, 2025

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 02, 2025

Pliant Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 02, 2025

Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Jan 02, 2025

Dec 31, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Position Boosted by Geode Capital Management LLC - Defense World

Dec 31, 2024

Dec 30, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.9%Time to Sell? - MarketBeat

Dec 30, 2024

Dec 29, 2024

Contrasting Pliant Therapeutics (NASDAQ:PLRX) & Bionomics (NASDAQ:BNOX) - Defense World

Dec 29, 2024

Dec 27, 2024

When (PLRX) Moves Investors should Listen - Stock Traders Daily

Dec 27, 2024

Dec 25, 2024

State Street Corp Raises Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Dec 25, 2024

Dec 23, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages - Defense World

Dec 23, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts - MarketBeat

Dec 23, 2024

Dec 20, 2024